t
Iconic Labs PLC announced it received a Conversion Notice from the European High Growth Opportunities Securitization Fund, dated 27 March 2023. This notice converted 50 Convertible Notes with an aggregate principal amount of £50,000 into 1,315,789,473 ordinary shares at a conversion price of £0.000038. Application is being made for these new shares to be admitted to trading on the London Stock Exchange on or around 31 March 2023, bringing the Company's total issued ordinary share capital to 43,106,916,660 Ordinary Shares.
| Date | 28 Mar 2023 |
| Time | 07:42:15 |
| Category | Corporate updates |
| ID | 4424U |
Iconic Labs PLC
("Iconic" or the "Company")
Conversion of Notes
Iconic Labs PLC (LSE:ICON), announces that it has received a valid Conversion Notice from the European High Growth Opportunities Securitization Fund.
The Conversion Notice was dated 27 March 2023 and provides for 50 Convertible Notes to be converted into 1,315,789,473 ordinary shares of £0.00001 ("Ordinary Shares") in the Company at a conversion price of £0.000038 at the aggregate principal amount of £50,000.
Application is being made for the 1,315,789,473 new Ordinary Shares to be admitted to trading on the Main Market of the London Stock Exchange which is expected to be on or around 31 March 2023. These shares rank pari passu with the existing Ordinary Shares of the Company.
Following the issue of these shares, the Company's issued ordinary share capital shall consist of 43,106,916,660 Ordinary Shares. The figure of 43,106,916,660 represents the total voting rights in the Company and should be used by shareholders as the denominator for the calculation by which they can determine if they are required to notify their interest in, or a change to their interest in, the Company under the Financial Conduct Authority's Disclosure Guidance & Transparency Rules.
This announcement contains inside information for the purposes of Article 7 of the Market Abuse Regulation (EU) 596/2014 as it forms part of UK domestic law by virtue of the European Union (Withdrawal) Act 2018 ("MAR"), and is disclosed in accordance with the Company's obligations under Article 17 of MAR.
For any further information or enquiries please contact: